Lupus Nephritis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Roche, Equillium, Argenx, Novartis, RemeGen, Annexon

Lupus Nephritis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Roche, Equillium, Argenx, Novartis, RemeGen, Annexon
DelveInsight Business Research LLP
As per DelveInsight’s assessment, globally, about 20+ key pharma and biotech companies are working on 20+ pipeline drugs in the Lupus Nephritis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Lupus Nephritis Pipeline Insight, 2023” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Lupus Nephritis Therapeutics Market. 

The report provides a detailed description of the Lupus Nephritis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Lupus Nephritis Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the key companies that are developing Lupus Nephritis therapies.

  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lupus Nephritis treatment.

  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • It navigates the emerging Lupus Nephritis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Lupus Nephritis treatment market.

Lupus Nephritis Therapeutics Analysis

Lupus Nephritis (LN), is one of the most severe organ manifestations of systemic lupus erythematosus (SLE) which is an autoimmune disorder leading to the loss of immune tolerance of endogenous nuclear material resulting in systemic autoimmunity that causes damage to various tissues and organs.

There are different types of lupus nephritis. Treatment is based on the type of lupus nephritis, which is determined by the biopsy. Since symptoms and severity vary from person to person, treatments are individually tailored to meet a person’s particular circumstances.  

The current treatment of lupus nephritis is still based on steroids, cyclophosphamide, azathioprine, and mycophenolate mofetil, which are non-selective immunosuppressive drugs that can inhibit multiple components of adaptive immunity. The treatment for LN varies with respect to the severity of the disease.

There are approx. 20+ key companies developing therapies for Lupus Nephritis. Currently, Roche is leading the therapeutics market with its Lupus Nephritis drug candidates in the most advanced stage of clinical development.

Lupus Nephritis Companies in the Therapeutics Market Include:

  • Roche

  • Horizon Therapeutics

  • Equillium

  • Argenx

  • AstraZeneca

  • Novartis

  • RemeGen

  • Annexon

And Many Others

Emerging and Marketed Lupus Nephritis Therapies Covered in the Report Include:

  • Obinutuzumab: Roche

  • Daxdilimab: Horizon Therapeutics

  • Itolizumab: Equillium

  • Secukinumab: Novartis

  • Guselkumab: Janssen Research & Development

  • Zanubrutinib: BeiGene

And Many More

Get an in-depth Assessment of the Emerging Therapies and Lupus Nephritis Companies Actively Working in the Market @

The Report Covers the Emerging Lupus Nephritis Therapies Under Different Phases of Clinical Development Like – 

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration – Lupus Nephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Intravenous

  • Subcutaneous

  • Parenteral

  • Topical

Molecule Type – Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

  • Polymer

  • Gene therapy

Mechanism of Action of the Emerging Therapies

  • CD6 antigen inhibitors

  • Agammaglobulinaemia tyrosine kinase inhibitors

  • Complement C5 inhibitor

  • Antibody-dependent cell cytotoxicity

  • Interleukin-23 subunit p19 inhibitors

  • PIM3 protein inhibitor

  • Dendritic cell inhibitor

  • IL17A protein inhibitors

Request for Sample PDF to Understand More About the Lupus Nephritis Treatment Outlook and Future Perspectives @

Table of Content

1. Report Introduction

2. Executive Summary

3. Lupus Nephritis Current Treatment Patterns

4. Lupus Nephritis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Lupus Nephritis Late-Stage Products (Phase-III)

7. Lupus Nephritis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Lupus Nephritis Discontinued Products

13. Lupus Nephritis Product Profiles

14. Lupus Nephritis Companies

15. Lupus Nephritis Drugs

16. Dormant and Discontinued Products

17. Lupus Nephritis Unmet Needs

18. Lupus Nephritis Future Perspectives

19. Lupus Nephritis Analyst Review  

20. Appendix

21. Report Methodology

Get Detailed Insights About the Reports Offerings @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Tonsillitis Market

“Tonsillitis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Tonsillitis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Tonsillitis market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States